TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
Open Access
- 29 January 2008
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1), 27
- https://doi.org/10.1186/1471-2407-8-27
Abstract
Taxane-platinum therapy (TP) has replaced platinum-based therapy (PC or PAC, DNA damaging chemotherapy) in the postoperative treatment of ovarian cancer patients; however, it is not always effective. TP53 protein plays a differential role in response to DNA-damaging agents and taxanes. We sought to define profiles of patients who benefit the most from TP and also of those who can be treated with PC.Keywords
This publication has 55 references indexed in Scilit:
- Geographical Variations in TP53 Mutational Spectrum in Ovarian CarcinomasAnnals of Human Genetics, 2006
- Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosisLeukemia, 2006
- Why TP53 status does not associate with clinical endpoints in ovarian cancer: Facts and hypothesesGynecologic Oncology, 2006
- Sense out of missenseNature, 2005
- Current Status of Taxane and Platinum-Based Chemotherapy in Ovarian CancerJournal of Clinical Oncology, 2003
- Treatment of platinum-resistant ovarian cancerExpert Opinion on Pharmacotherapy, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.Journal of Clinical Investigation, 1997
- p53 and apoptosisBritish Medical Bulletin, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996